Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer
September 30 2019 - 4:15PM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, announced today the appointment of Bettina M. Cockroft,
MD, MBA, as Senior Vice President and Chief Medical Officer. Dr.
Cockroft will oversee all clinical development activities and
operations and will report to the Executive Vice President of
Research and Development.
“Bettina brings over 20 years of clinical development
experience, having worked across multiple therapeutic areas and
leading programs in several countries,” said Adrian Woolfson, BM.,
B.Ch., Ph.D., Executive Vice President, Research and Development.
“This is an important time to welcome Bettina to Sangamo, as we
expect a steady flow of readouts from our ongoing clinical trials
and expect to initiate additional trials in the coming year. We
look forward to Bettina’s contributions and believe she will be a
key player in helping us realize our mission of translating our
groundbreaking science into genomic medicines that transform
patients’ lives.”
Dr. Cockroft has 23 years of experience in the biopharmaceutical
industry and joins Sangamo from Cytokinetics, Inc., where she was a
member of the senior leadership team responsible for clinical
development of fast skeletal muscle troponin activators in diseases
such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy.
Before that, Dr. Cockroft served as Chief Medical Officer of Auris
Medical AG, where she led and grew the clinical development team
responsible for two Phase 3 programs. Dr. Cockroft also held roles
of increasing responsibility at Merck Serono S.A., Novartis
Consumer Health and Menarini Ricerche earlier in her career.
Dr. Cockroft earned her MBA at MIT Sloan School of Management
and her MD from the University of Genoa.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, ex vivo gene-edited cell
therapy, and in vivo genome editing and gene regulation. For more
information about Sangamo, visit www.sangamo.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190930005140/en/
Investor Relations – Global McDavid
Stilwell 510-970-6000, x219 mstilwell@sangamo.com
Media Inquiries – Global Aron
Feingold 510-970-6000, x421 afeingold@sangamo.com
Investor Relations and Media Inquiries –
European Union & United Kingdom Caroline Courme 33 4 97
21 27 27 ccourme@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Sep 2023 to Sep 2024